Caris Life Sciences Finalizes Achieve 1 Study Results Reinforcing the Superior Sensitivity and Specificity of Caris Detect

Core Insights - Caris Life Sciences has finalized the Achieve 1 Study results, demonstrating the superior sensitivity and specificity of its multi-cancer early detection test, Caris Detect, compared to traditional methylation-based approaches [1][9]. Group 1: Study Results - The Achieve 1 Study involved 3,014 subjects and assessed Caris Detect's diagnostic accuracy in identifying multiple cancer types at early stages through peripheral blood sampling [3]. - Sensitivity rates for different cancer stages were reported as follows: - Stage I: 56.8% - Stage II: 67.7% - Stage III: 79.0% - Stage IV: 98.6% [3][4]. - Asymptomatic specificity was recorded at 99.2%, while benign/high-risk specificity was 96.0% [4]. Group 2: Cancer Type Sensitivity - Sensitivity for specific cancer types in Stage I and II included: - Breast: 53.7% - Prostate: 74.1% - Lung: 73.4% - Uterus: 60.6% - Bowel: 61.8% [4][5][6][8]. - The study highlighted that the Whole Genome Sequencing approach effectively detects diverse molecular changes driving cancer, reinforcing the need for comprehensive biological analysis for early detection [9]. Group 3: Company Overview - Caris Life Sciences is a leading AI TechBio company focused on precision medicine, utilizing advanced molecular profiling and AI to develop innovative healthcare solutions [10]. - The company has processed over 1 million cases and generated more than 50 billion molecular markers, forming a robust foundation for its AI models [2]. - Caris aims to enhance its testing capabilities by incorporating additional pillars, such as Whole Transcriptome Sequencing, to improve overall test performance [9].